Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or, Peter A.J. Calabresi, Douglas Arnlod, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith

Research output: Contribution to journalArticlepeer-review

353 Scopus citations


We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalAnnals of neurology
Issue number3
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial'. Together they form a unique fingerprint.

Cite this